GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Stay updated with the latest stock market news and live updates. Get real-time insights on Sensex Today, Nifty Live, stock market today, IPO news and more on Business Standard.

It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- Save ...

Pending: A vacant office block in Maidenhead could be turned into a large self-storage facility. Eurasia House in Concorde ...

Board Meeting Intimation for Board Meeting Intimation - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, expert ...

Gen Z's preference for convenient formats like gummies and effervescent powders, coupled with rising health awareness, is ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the release of ...